PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
December 14 2022 - 8:00AM
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD),
a clinical stage biopharmaceutical company focusing on the
development of novel anti-purinergic drug therapies (“APT”) for the
treatment of disorders with intractable neurologic symptoms, today
announced that the Company has launched a newly updated corporate
website at www.paxmedica.com.
Howard Weisman, Chief Executive Officer of
PaxMedica, commented, “Our new website underscores our ongoing
commitment to develop therapeutic advancements to treat core
symptoms of autism and other potentially related disorders with
intractable neurologic symptoms. The refreshed site represents the
first step in providing a more robust platform for sharing
information with our stakeholders, including families and
investors, who are interested in our research.”
The new website provides easy access to essential
information and other features while offering a more comprehensive
understanding of PaxMedica’s focus on developing treatments for
disorders with intractable neurologic symptoms such as Autism
Spectrum Disorder (“ASD”). Key features of the refreshed website
include an updated design and a more engaging interface, as well as
better segmentation of the key subjects and sections.
About PaxMedicaPaxMedica is a clinical
stage biopharmaceutical company focusing on the development of
anti-purinergic drug therapies (“APT”) for the treatment
of disorders with intractable neurologic symptoms,
ranging from neurodevelopmental disorders, including Autism
Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive
disorder believed to be viral in origin and now with rising
incidence globally due to the long term effects of SARS-CoV-2
(“COVID-19”). One of PaxMedica’s primary points of focus is the
development and testing of its lead program, PAX-101, an
intravenous formulation of suramin, in the treatment of ASD and the
advancement of the clinical understanding of using that agent
against other disorders such as ME/CFS and Long COVID-19 Syndrome,
a clinical diagnosis in individuals who have been previously
infected with COVID-19. For more information, please
visit: www.paxmedica.com
Forward-Looking StatementsThis press
release contains “forward-looking statements.” Forward-looking
statements reflect our current view about future events. These
forward-looking statements involve known and unknown risks and
uncertainties and are based on the Company’s current expectations
and projections about future events that the Company believes may
affect its financial condition, results of operations, business
strategy and financial needs. Investors can identify these
forward-looking statements by words or phrases such as “may,”
“will,” “could,” “expect,” “anticipate,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “is/are likely to,” “propose,”
“potential,” “continue” or similar expressions. The Company
undertakes no obligation to update or revise publicly any
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company’s registration statement. most recent
quarterly reports and other filings with the U.S. Securities and
Exchange Commission.
Contacts:
ir@paxmedica.com
Stephanie PrincePCG
Advisorysprince@pcgadvisory.com(646) 863-6341
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024